URGN News and Press, UroGen Pharma Ltd. From 04/17/24

Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term real-world analyses of JELMYTO® (mitomycin) for pyelocalyceal solution exploring its use in broad pa...

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process, simplify the reconstitution procedure, and potentially extend intellectu...

2024-04-09 09:35:59 ET More on S&P 500 Index: This So-Called Permabull Remains Bullish For Good Reason The Epic Rally Will Probably Continue The March CPI Report Is Expected To Be Hot For The Third Straight Month Nasdaq, S&P, Dow rise and yields inch ...

2024-04-03 08:28:03 ET More on Teva , UroGen Pharma, etc. Teva Pharmaceutical Industries: Potential Outweighs Concerns UroGen: All Eyes On UGN-102 UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript Teva and Viatris revives chance to dispute J&J's ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Tev...

2024-03-26 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-18 07:35:24 ET Summary JELMYTO revenues are growing but not by enough to support UroGen's operations. Guided financials show ongoing losses with adequate liquidity for its near term UGN-102 development. If all goes as hoped UroGen will launch UGN-102 in Q1, 2025. ...

2024-03-16 08:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 20:13:09 ET UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Conference Call March 14, 2024, 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Dong Kim - CFO Je...

2024-03-14 08:26:50 ET More on UroGen Pharma Urogen: Binary Bet On UGN-102 UroGen falls as Teva seeks FDA nod for Jelmyto generic Seeking Alpha’s Quant Rating on UroGen Pharma Read the full article on Seeking Alpha For further details see: ...